Biomarkers and related uses for treating liver damage with THR-β agonists
The method of THR-β agonist dose adjustment based on biomarker testing effectively treats NASH, addressing the lack of therapy for this progressive liver disease and improving liver health outcomes.
JP2026521649APending Publication Date: 2026-06-30MADRIGAL PHARMACEUTICALS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- MADRIGAL PHARMACEUTICALS INC
- Filing Date
- 2024-06-20
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
There is no specific therapy for non-alcoholic steatohepatitis (NASH), a progressive liver disease that can lead to cirrhosis and fibrosis, with a high mortality rate, affecting a significant portion of the U.S. population.
Method used
A method involving baseline biomarker testing, administration of a first dose of a thyroid hormone receptor-β (THR-β) agonist, followed by standard biomarker testing to determine a second dose, and subsequent administration of the THR-β agonist to treat or prevent liver damage.
Benefits of technology
This approach effectively treats or prevents liver damage by utilizing THR-β agonists, as demonstrated by improvements in liver fat reduction and NASH resolution in clinical trials.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026521649000001_ABST
Abstract
This disclosure provides a method for treating or preventing liver damage (e.g., NASH) in a subject using a THR-β agonist with the help of a biomarker test (e.g., determining the dose of the THR-β agonist).
Need to check novelty before this filing date? Find Prior Art